Latest kidney diseases Stories

EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population

2013-02-07 08:25:44

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts: (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)...

EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations

2013-02-05 08:36:15

EXTON, Penn., Feb. 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' report, ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, which contains data from 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts: On average, nephrologists in the EU5 countries...

Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis

2013-01-28 08:28:24

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced successful top-line results from the long-term Phase 3 study of Zerenex(TM) (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint, described below,...

Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 3 Long-Term Study

2013-01-27 20:20:16

NEW YORK, Jan. 27, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) will host a conference call tomorrow, Monday, January 28, at 8:00am ET to review the top-line results from the Phase 3 long-term study component of its Phase 3 registration program of Zerenex((TM)) (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. Keryx...

Pentec Health Granted UK Patent for PROPLETE®

2013-01-15 23:03:57

Patent is a First in Europe, Expands Global Market for Pentec Philadelphia, Pennsylvania (PRWEB) January 15, 2013 In a move to expand its geographic reach to international markets and further implement the strategic growth plan of the company, Pentec Health, Inc. today announced that it has been awarded a patent by the Intellectual Property Office of the United Kingdom for its speciality pharmacy compounded prescription renal formulation, PROPLETE®. Pentec’s geographic expansion is...

Dialysis Patient Citizens Announces Creation of DPC Education Center

2013-01-15 12:28:01

New Affiliate Organization Will Empower Kidney Disease Patients through Education WASHINGTON, Jan. 15, 2013 /PRNewswire-USNewswire/ -- Today, Dialysis Patient Citizens (DPC) announced the creation of a new affiliate organization, the DPC Education Center (The Center). The new organization, which is incorporated as a 501(c)(3) non-profit, will work together with DPC to advance their shared mission of improving the quality of life of all kidney disease and end stage renal disease...

Drug Fails To Help Kidney Transplant Recipients

2013-01-11 13:19:05

Results come from large, randomized, placebo-controlled trial Highlight: -While safe and well-tolerated, angiotensin II blockade did not lessen tissue scarring or prevent kidney failure in kidney transplant recipients. -Angiotensin II blockade is known to slow kidney disease progression in individuals without transplants. A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to...

Triple Mix Of Blood Pressure Drugs And Painkillers Linked To Kidney Problems

2013-01-09 12:26:44

Absolute risk still low, but doctors and patients should be vigilant Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com today. Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers. Acute kidney injury (also known as kidney failure) is a major...

OPKO Health to acquire privately held Cytochroma

2013-01-08 20:21:23

Acquisition Includes Replidea(TM) and Alpharen(TM), Both in Phase 3 Clinical Trials with Kidney Disease Patients MARKHAM, ON, Jan. 8, 2013 /PRNewswire/ - Cytochroma today announced that it has entered into a definitive agreement with OPKO Health, Inc. (NYSE:OPK) under which Cytochroma, a privately held pharmaceutical company with operations in Markham, ON and Bannockburn, IL, will be acquired by OPKO. Through this transaction, OPKO will acquire worldwide rights to Cytochroma's two...

Although Usage Remains Low Six Months Post-Launch, U.S. Nephrologists Continue to Report High Anticipated Future Use of Omontys

2013-01-08 08:30:19

EXTON, Pa., Jan. 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the third wave (W3) of its LaunchTrends(®): Omontys report fielded approximately six months post-U.S. commercial availability. This report surveyed a total of 81 U.S. nephrologists about their current awareness, trial and usage of Affymax / Takeda's Omontys (peginesatide). Omontys is an...